Immuno-Oncology Research Applications

Great strides have been made in the field of cancer research as a result of harnessing native and modified cells of the immune system. Therapies using genetically modified T-cells have proven to be effective against certain hematologic malignancies. Antibodies that bind to checkpoint ligands and receptors have immensely increased the effectiveness of drug treatments and cell therapies against many types of cancers.

Discover new combinations with the quality and performance you expect from MSD.

  U-PLEX Assay Designer
Use the U-PLEX Assay Designer to create custom multiplex assays from a selection of MSD assays, your own antibodies, or a combination of both.

U-PLEX Combinations for Immuno-Oncology Research

U-PLEX Combos represent popular combinations of assays, grouped into separate catalog numbers for ordering convenience.

Species	Name	Catalog Number	Assays
Human	Angiogenesis Combo 1	K15339K NEW	FGF (basic), PlGF, Tie‑2, VEGF‑A, VEGF‑D
Human	CAR-T Cell Combo 1	K15338K NEW	GM‑CSF, Granzyme A, Granzyme B, IFN‑γ, IL‑2, TNF‑α
Human	Effector Cell Checkpoint Combo 1	K15341K NEW	CD27, CD28, CD40L (soluble), CTLA‑4, GITR/TNFRSF18, HAVCR2/TIM‑3, LAG3, OX40/TNFRSF4, PD1 (epitope 1), TIGIT
Human	Macrophage M1 Combo 1	K15336K NEW	IL-1β, IL-6, IL-12p70, IL-18, IL-23, IP-10, MCP-1, MIP-1α, TNF-α
Human	Macrophage M2 Combo 1	K15337K NEW	Eotaxin-2, IL-4, IL-10, IL-13, M-CSF, MDC, TARC
Human	Target Cell Checkpoint Combo 1	K15340K NEW	CD276/B7‑H3, GITRL/TNFSF18, PD‑L1 (epitope 1), PD‑L2
Human	Immuno-Oncology Group 1 111-Plex	K15342K NEW	BAFF, BAFF‑R/TNFRSF13C, BDNF, BCMA/TNFRSF17, CD20, CD27, CD276/B7‑H3, CD28, CD40L (soluble), C‑Peptide, CTACK, CTLA‑4, ENA‑78, Eotaxin, Eotaxin‑2, Eotaxin‑3, EPO, FGF (basic), FGF‑23, FLT3L, Fractalkine, FSH, G‑CSF, Ghrelin (active), Ghrelin (total), GIP (active), GIP (inactive), GIP (total), GITR/TNFRSF18, GITRL/TNFSF18, GLP‑1 (active), GLP‑1 (inactive), GM‑CSF, gp130 (soluble), Granzyme A, Granzyme B, GRO‑α, HAVCR2/TIM‑3, I‑309, IFN‑α2a, IFN‑β, IFN‑γ, IL‑1α, IL‑1β, IL‑1RA, IL‑2, IL‑2Rα, IL‑3, IL‑4, IL‑5, IL‑6, IL‑7, IL‑8, IL‑9, IL‑10, IL‑12/IL‑23p40, IL‑12p70, IL‑13, IL‑15, IL‑16, IL‑17A, IL‑17A/F, IL‑17C, IL‑17D, IL‑17E/IL‑25, IL‑17F, IL‑18, IL‑21, IL‑22, IL‑23, IL‑27, IL‑29/IFN‑λ1, IL‑31, IL‑33, Insulin, IP‑10, I‑TAC, LAG3, Leptin, LH, MCP‑1, MCP‑2, MCP‑4, M‑CSF, MDC, MIF, MIP‑1α, MIP‑1β, MIP‑5, OX40/TNFRSF4, PD1 (epitope 1), PD1 (epitope 2), PD‑L1 (epitope 1), PD‑L2, PIGF, PP, Proinsulin, PYY (total), RANKL/TNFSF11, SDF‑1α, Tie‑2, TIGIT, TLR1, TNF‑α, TNF‑β, TPO, TRAIL, TSLP, VEGF‑A, VEGF‑D, YKL‑40
Mouse	Macrophage M1 Combo 1	K15408K NEW	IL-1β, IL-6, IL-12p70, IL-15, IL-23, IP-10, MCP-1, MIP-1α, TNF-α
Mouse	Macrophage M2 Combo 1	K15409K NEW	IL-4, IL-10, IL-13, MDC, TARC

New Immuno-Oncology Assays

Individual assays can be configured into customized multiplex assays of your choice in either 96- or 384-well plates.

Combine MSD assays with your own assays or with R-PLEX Antibody Sets for a truly custom multiplex.